Rappta Therapeutics (“Rappta”), focused on developing first-in-class anti-cancer drugs activating protein phosphatase … Continue reading “Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs”
Backed by Omega Funds to develop new oral treatments for rare autoimmune diseases. … Continue reading “Chord Therapeutics launches with USD 16 million Series A financing from Omega Funds”
Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Seeds co-leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A drugs”
Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical … Continue reading “Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020”
– Future of healthcare conference in partnership with Dechert LLP goes virtual … Continue reading “Optimum Strategic Communications 12th Annual Healthcare Investor Conference”
9% secured convertible bonds replace €5 million in Kreos debt Conversion price … Continue reading “Kiadis announces the placement of €5 million convertible bonds with Kreos”
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the last visit of the … Continue reading “The 200th patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020”
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces their … Continue reading “BaseLaunch announces that Johnson & Johnson Innovation has renewed its commitment becoming latest strategic partner in the second phase”
London, UK ValiRx (AIM:VAL) reports today that it has received headline results from … Continue reading “VAL201 Clinical Trial Update Headline results demonstrate VAL201 has potential to be a safe and well-tolerated drug”
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate … Continue reading “Synklino raises seed round to develop breakthrough infection treatment for transplant patients”
Funds will support preparations for potential EU conditional approval of GB0139 in … Continue reading “Novo Seeds Portfolio Company Galecto Raises USD 64 Million to Accelerate Development of Clinical Pipeline”
Eight top-tier investment firms have partnered with the life science incubator BioInnovation … Continue reading “BioInnovation Institute partners with eight interna-tional VCs”
22 September 2020 Permira funds to acquire leading European CNS specialty pharmaceutical … Continue reading “Permira Funds To Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm”
Salvia BioElectronics B.V., a neurostimulation platform company targeting chronic migraine, today announced … Continue reading “Salvia BioElectronics raises EUR 26M (USD 31M) to develop innovative neurostimulation therapy for chronic migraine”
22 September 2020, London, Geneva & Jersey: Medicxi, the leading European life sciences … Continue reading “Medicxi announces the closing of its first €200 million Secondary Fund, led by Pantheon with co-lead LGT Capital Partners”
Novo Ventures, the ventures arm of Novo Holdings, today announced that it … Continue reading “NOVO VENTURES CO-LEADS US$83M SERIES C FINANCING IN LAVA THERAPEUTICS”
ALAMEDA, Calif. and BASEL, Switzerland – September 8, 2020 – Exelixis, Inc. (Nasdaq: … Continue reading “Exelixis and NBE-Therapeutics Enter into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer”
SOUTH SAN FRANCISCO, Calif. (August 13, 2020) Mission Bio, Inc., the pioneer in high-throughput … Continue reading “Mission Bio Raises $70M in Series C Funding Led by Novo Holdings to Accelerate Development of Cancer Therapies with Single-cell Multi-omics”
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, and Bionical Emas, a … Continue reading “G1 Therapeutics, Inc. and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
